MDNA Medicenna Therapeutics Corp.

FDA Catalyst Company
1.06
-0.02  -2%
Previous Close 1.08
Open 1.24
52 Week Low 0.912
52 Week High 4.02
Market Cap $58,905,126
Shares 55,996,644
Float 55,570,874
Enterprise Value $43,158,656
Volume 17,810
Av. Daily Volume 125,523
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 06/01/2021

Latest News

  1. -- New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity)

    -- MDNA11 selectively increased a sub-population of anti-tumor ICOS+ CD8 T cells without enhancing proliferation of highly immune-suppressive pro-tumor ICOS+ Treg cells

    -- Dose-dependent and 3-fold increase in immune cells expressing Granulysin, a peptide known to target tumor cell killing.

    TORONTO and HOUSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that clinical data from the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY) study of MDNA11, the…

    View Full Article
  2. -- Levels of Ki67+ expression by CD8+ T cells and NK cells increased by 17-fold and 10-fold, respectively, in the third cohort (30 µg/kg dose) when compared to baseline

    -- NK cell / Treg and CD8+T cell / Treg ratios increased by 4.4-fold and 2.6 fold, respectively, at the 30 µg/kg dose, demonstrating superior stimulation of cancer fighting immune cells.

    -- Significant dose-dependent increases in CD8+ T (>3-fold) and NK (>6-fold) cells indicates potential for further expansion of anti-tumor immune cells as dose-escalation continues

    TORONTO and HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced new clinical…

    View Full Article
  3. TORONTO and HOUSTON, April 27, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President and CEO and Elizabeth Williams, CFO of Medicenna, will attend the conference and present a corporate overview at the 2022 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place from May 2 – May 3, 2022.

    Details are as follows:

    2022 Bloom Burton & Co. Healthcare Investor Conference
    Date:   Monday, May 2nd
    Time:     3:00pm EDT
    Location: Metro Toronto Convention Centre, North Building,
      255 Front St W, Toronto, Ontario
    Webcast: Webcast Link

    Webcast and replay information for this event…

    View Full Article
  4. -- Anti-PD1-IL-2 BiSKIT (Bi-functional SuperKines for ImmunoTherapy) selectively stimulates anti-cancer immune cells via IL-2 agonism and prevents their exhaustion through PD-1 inhibition

    -- Treatment with anti-PD-1-IL-2 BiSKIT led to statistically significant improvements in tumor growth inhibition and survival compared to the co-administration of its underlying components

    -- Data highlight the versatility of the Superkine platform and the advantages of using a cis-binding approach to enhance the efficacy of checkpoint blockade

    TORONTO and HOUSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced new preclinical…

    View Full Article
  5. -- Fc-MDNA413 suppresses pro-tumor immune pathways by simultaneously inhibiting IL-4 / IL-13 mediated signaling and proliferation via the Type II IL-4 receptor

    -- Fc-MDNA413 inhibits in vivo tumor growth alone and in combination with an IL-2 super-agonist in a murine cancer model

    -- Ability of Fc-MDNA413 to selectively block Type II IL-4 receptor activity in the tumor micro-environment (TME) may be effective in treating immunologically "cold" tumors

    TORONTO and HOUSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced new preclinical data on its long-acting IL-13 super-antagonist, Fc-MDNA413, in an electronic…

    View Full Article
View All Medicenna Therapeutics Corp. News